Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Solving the Puzzle of Hans' Algorithm (HA) Methodological Shortcomings: Canadian Harmonization of Hans' Algorithm for Diffuse Large B-Cell Lymphoma (DLBCL) and Development of Fit-for-Purpose Modified Hans' Algorithm (mHA).

Applied immunohistochemistry & molecular morphology : AIMM·2026

Same author

Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade.

Molecular cancer therapeutics·2025

Same author

Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity.

Cancer research·2025

Same author

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses.

Cancer immunology, immunotherapy : CII·2025

Same author

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses.

Research square·2025

Same author

DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities.

Clinical epigenetics·2025

Same journal

A Biologically Dominant Trophoblastic Component Guiding Neoadjuvant EMA/CO in Endometrial Carcinoma: A Clinical Case Report.

Clinical case reports·2026

Same journal

Could Fabry Disease Cause Giant Coronary Aneurysms in a 7-Month-Old Infant: A Case Report.

Clinical case reports·2026

Same journal

Correction to "Loss of Consciousness in a Child Following Accidental Ingestion of Brimonidine Ointment: A Case Report".

Clinical case reports·2026

Same journal

Simultaneous Transvenous Lead Extraction and Intra-Operative Epicardial Extravascular Defibrillator (EV-ICD) Implantation During Tricuspid Valve Replacement.

Clinical case reports·2026

Same journal

Successful Surgical Management of Chronic Subdural Hematoma in a Patient With Severe Thrombocytopenia due to Aplastic Anemia: A Case Report.

Clinical case reports·2026

Same journal

Appendix Mucinous Neoplasm.

Clinical case reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 24, 2025

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Pure erythroid leukemia.

Méghan Forest¹, Simon F Roy¹, Michelle Houde¹

¹Department of Pathology University of Montréal Montréal QC Canada.

Clinical Case Reports

|December 28, 2020

Summary

This summary is machine-generated.

Pure erythroid leukemia (PEL) is an aggressive acute leukemia. Characterized by over 80% erythroid precursors in bone marrow, PEL has a poor prognosis.

Keywords:

AML bone marrow pathology hematological oncology pancytopenia pure erythroid leukemia

More Related Videos

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Published on: December 14, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Experiment Videos

Last Updated: Nov 24, 2025

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Published on: December 14, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Area of Science:

Hematology
Oncology
Leukemia Research

Background:

Pure erythroid leukemia (PEL) is a rare subtype of acute leukemia.
It is characterized by a predominant erythroid lineage without a significant myeloblastic component.
PEL follows a particularly aggressive clinical course with poor outcomes.

Purpose of the Study:

To define the key diagnostic criteria for pure erythroid leukemia.
To highlight the aggressive nature and poor prognosis associated with this leukemia subtype.
To emphasize the importance of accurate diagnosis for appropriate patient management.

Main Methods:

Morphological examination of bone marrow aspirates.
Immunophenotyping to confirm erythroid lineage and absence of myeloid markers.
Cytogenetic and molecular studies to identify prognostic factors.

Main Results:

Diagnosis requires >80% of bone marrow cellularity to be of erythroid lineage.
At least 30% of nucleated cells must be proerythroblasts.
Absence of significant myeloblastic component is a key differentiator.

Conclusions:

Pure erythroid leukemia is a distinct and aggressive entity within acute leukemias.
Accurate identification based on strict morphological and immunophenotypic criteria is crucial.
Early recognition facilitates appropriate treatment strategies for this challenging leukemia.